Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propiomazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.96 |
| ▸ | HTR1A | P08908 | 6/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.96 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.96 |
| ▸ | DRD3 | P35462 | 6/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.96 |
| ▸ | DRD2 | P14416 | 3/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 2/20 | 0.96 |
| ▸ | HTR2C | P28335 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | HTR2B | P41595 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | MTOR | P42345 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propiomazine SCHEMBL29609596 | 0.98 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL29370554 | 0.98 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| (R)-Propiomazine SCHEMBL6910697 | 0.98 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL93770 | 0.98 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL30903904 | 0.97 | CHRM2 (0.98) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL141677 | 0.97 | CHRM2 (0.98) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL6372719 | 0.97 | CHRM2 (0.98) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL3863991 | 0.92 | CHRM2 (0.88) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| SCHEMBL10368273 | 0.86 | CHRM2 (0.79) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Aceprometazine SCHEMBL142393 | 0.86 | HTR1A (0.79) | CHRM2HTR1ACHRM1ADRA1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483487-A1 | MLINC | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen (DE) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023161010-A1 | MLINC | RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE (RWTH) AACHEN (DE) | 2023-08-31 | — | — | WO | disclosed |
| US-10722562-B2 | Combinatorial analysis and repair | IMMUDEX APS (DK) | 2020-07-28 | — | — | US | disclosed |
| US-20160361356-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2016-12-15 | — | — | US | disclosed |
| EP-2949212-A1 | USE OF OXYGEN ANTAGONISTS FOR EX VIVO PRESERVATION OF TISSUES OR ORGANS | Fred Hutchinson Cancer Research Center (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150164064-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2015-06-18 | — | — | US | disclosed |
| US-8822535-B2 | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-09-02 | — | — | US | disclosed |
| CN-1901795-B | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HUTCHINSON FRED CANCER RES | 2014-03-26 | — | — | CN | disclosed |
| EP-1879599-B1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | HUTCHINSON FRED CANCER RES (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-11-08 | — | — | US | disclosed |
| EP-1689228-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | Fred Hutchinson Cancer Research Center (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1684580-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684579-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-08-04 | — | — | US | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
| US-6650679-B1 | Preionization arrangement for gas laser | LAMBDA PHYSIK AG (DE) | 2003-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361356-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | BCL2, BAX, HSF1 | HRH1 2493/4885CHRM2 3210/4885HTR1A 2012/4885 |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | HRH1 2287/4885CHRM2 3064/4885HTR1A 4061/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | HRH1 1709/4885CHRM2 3821/4885HTR1A 3278/4885 |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | HIF1A, HIF1AN, EGLN3 | HRH1 2221/4885CHRM2 4789/4885HTR1A 3939/4885 |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | PLAT, TBXA2R, THPO | HRH1 3316/4885CHRM2 3976/4885HTR1A 2983/4885 |
| US-20150164064-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | HSF1, HSP90AB1, HSP90AA1 | HRH1 1709/4885CHRM2 3821/4885HTR1A 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.